A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. [electronic resource]
Producer: 20170808Description: 1-10 p. digitalISSN:- 1879-0852
- Abdominal Pain -- chemically induced
- Administration, Oral
- Adult
- Aged
- Allosteric Regulation
- Anorexia -- chemically induced
- Bile Duct Neoplasms -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cholangiocarcinoma -- drug therapy
- Chromatography, High Pressure Liquid
- Chromatography, Liquid
- Colorectal Neoplasms -- drug therapy
- Diarrhea -- chemically induced
- Drug Eruptions -- etiology
- Esophageal Neoplasms -- drug therapy
- Fatigue -- chemically induced
- Female
- Glycogen Synthase Kinase 3 beta -- drug effects
- Humans
- Lung Neoplasms -- drug therapy
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Kinase 2 -- antagonists & inhibitors
- Male
- Maximum Tolerated Dose
- Mesothelioma -- drug therapy
- Middle Aged
- Mitogen-Activated Protein Kinase 1 -- drug effects
- Mitogen-Activated Protein Kinase 3 -- drug effects
- Nausea -- chemically induced
- Neoplasms -- drug therapy
- Pancreatic Neoplasms -- drug therapy
- Phosphoproteins -- drug effects
- Protein Kinase Inhibitors -- adverse effects
- Proto-Oncogene Proteins c-akt -- drug effects
- Ribosomal Protein S6 Kinases, 70-kDa -- drug effects
- Tandem Mass Spectrometry
- Uterine Cervical Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.